NCT02772614View on ClinicalTrials.gov

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Parkinson's Disease
Interventions
DRUG

BIA 3-202 (200 mg)

200 mg powder for oral use of unlabelled BIA 3-202

Trial Locations (1)

CH-4123

Swiss Pharma Contract Ltd, Allschwil

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02772614 - Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites | Biotech Hunter | Biotech Hunter